Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2020 Oct 9;15(10):e0240031. doi: 10.1371/journal.pone.0240031

Active household contact screening for tuberculosis and provision of isoniazid preventive therapy to under-five children in Afghanistan

Said Mirza Sayedi 1,*, Mohammad Khaled Seddiq 2, Mohammad K Rashidi 1, Ghulam Qader 1, Naser Ikram 3, Muluken Melese 4, Pedro G Suarez 4
Editor: Philip C Hill5
PMCID: PMC7546473  PMID: 33035249

Abstract

Objectives

This observational study analyzed the performance of the National TB Control Program (NTP) in Afghanistan in household contact screening from 2011 to 2018 and its use as an entry point for isoniazid preventive therapy (IPT), as well as the IPT completion rates for children under age five.

Methods

From 2011 to 2018, the Afghanistan NTP released guidelines for passive and active contact screening of bacteriologically confirmed TB cases. Health workers were trained in contact screening. Presumptive TB cases gave sputum for AFB smear microscopy; other diagnostics were used if patients could not produce sputum. Children under five (excluding those with active TB) were treated for latent TB infection. We calculated the yield and the number needed to screen and number needed to test to find a case of TB, as well as the rates of IPT initiation and completion.

Results

From 2011 to 2018, 142,797 bacteriologically confirmed TB cases were diagnosed in Afghanistan. The number of household members eligible for screening was estimated to be 856,782, of whom 586,292 (81%) were screened for TB and 117,643 (20.1%) were found to be presumptive TB cases. Among the cases screened, 10,896 TB cases (all forms) were diagnosed (1.85%, 95% CI 1.82–1.89), 54.4% in females. The number needed to screen to diagnose a single case of TB (all forms) was 53.8; the number needed to test was 10.7. Out of all children under five, 101,084 (85.9%) were initiated on IPT, and 69,273 (68.5%) completed treatment.

Conclusions

Program performance in contact screening in Afghanistan is high, at 81%, and the yield of TB is also high—close to 10 times higher than the national TB incidence rate. IPT initiation and completion rates are also high as compared to those of many other countries but need further improvement, especially for completion.

Introduction

Tuberculosis (TB) is a major global public health problem and represents 1 of the top 10 causes of death globally. In 2018, an estimated 10 million people developed TB disease, which caused death in 1.5 million people [1]. In 2018, a total of 7 million new TB cases were notified by national health authorities and reported to the World Health Organization (WHO), but more than 3 million TB cases were missed [1]. Although Afghanistan is not on WHO’s list of the 30 high-TB-burden countries, the incidence of TB is as high as in some of the high-burden countries, with a rate of 189 per 100,000 population, which has remained the same since 2000, although treatment coverage has greatly improved, from 19% in 2000 to 69% in 2018. In 2018, Afghanistan reported 48,420 TB cases out of the estimated 70,000 incident cases [1].

One strategy to increase case detection is contact screening of bacteriologically confirmed TB index cases. In 2011, the National TB Control Program (NTP) of Afghanistan initiated passive household contact screening, whereby bacteriologically confirmed index TB patients are counseled to bring their contacts for screening, and active household contact screening was also implemented in selected provinces [2]. In 2014, active household contact screening was expanded to Kabul and in 2015 further expanded to another five provinces. Contact screening was also used as an entry point to implement isoniazid preventive therapy (IPT) for children under five.

Although contact screening is a high-yield intervention recommended by WHO [3], its yield differs based on the country disease burden, diagnostic methods used, and health workers’ capacity. The reported yield of contact screening ranges from 656 per 100,000 population [4] to 1,788 per 100,000 population in Viet Nam [5], 914 per 100,000 in Peru [6], 610 per 100,000 in Ethiopia [7], and 2,200 per 100,000 in Pakistan [8]. In an Afghanistan study of household contact screening that reported only on smear-positive cases, the yield was 1,880 per 100,000 population in the first year and decreased to 1,400 per 100,000 in the second year of intervention [9]. The yield was almost 10 times higher than the national estimated incidence of 189 per 100,000 population for Afghanistan [1].

This article analyzes the routine contact screening performance of the Afghanistan NTP from 2011 to 2018, with a focus on how contact screening helped expand IPT for children under five.

Methods

Setting

The Afghanistan NTP was initiated in 1954 by the Ministry of Public Health (MOPH), and the directly observed treatment short course (DOTS) strategy was introduced in 1997 but not rolled out nationwide until 2002 due to the security situation in the country [2]. The TB control program is integrated into primary and secondary health services through the Basic Package of Health Services and Essential Package of Hospital Services. Currently 2,627 health facilities in the country provide DOTS services, and 883 laboratories carry out sputum microscopy (MOPH, National TB Report 2018). The TB program has been relatively well funded through the Global Fund, USAID, and other major donors; this support has built capacity in the health care system to diagnose and manage the TB prevention and control program. The relative improvement in the country’s security situation also provided an opportunity to strengthen the TB program.

The national reporting system collected the results of routine contact screening for all 34 provinces from 2011 to 2018, following the implementation policy of the NTP. This study presents this programmatic experience, including only the public sector since the private sector was not engaged in contact screening and IPT administration. Before 2011, there was no contact screening policy or reporting. The national guidelines recommend both active and passive contact screening of the household members of bacteriologically confirmed index TB patients [10]. After a new index TB patient is identified and registered for treatment, TB experts counsel the index patient to bring his/her contacts to the health facility for screening, which is the passive screening approach, or a health worker or a community health worker (CHW) visits the house of the index TB patient to screen all household members, which is the active screening approach [10, 11].

The health worker, per the national guideline, asks each family member of the index TB patient if s/he has signs and symptoms of TB (productive cough for more than two weeks, weight loss, fever, and loss of appetite). Identified presumptive TB cases then give spot sputum, which is transported to an acid-fast bacilli (AFB) smear microscopy center on the same day. For the morning and spot sputum collection, the person with presumptive TB is asked to go to the health facility. At the health facility, people with presumptive TB are asked again about symptoms and signs, receive physical exams, and give sputum. If the sputum smear or GeneXpert test is negative, but there is a high degree of suspicion of TB or another disease, other investigations, such as chest x-rays, are undertaken. Per the national guidelines, two smears should be positive to support a diagnosis of TB. If only one smear out of three is positive, the doctor decides whether other investigations are warranted and starts treatment with a broad-spectrum antimicrobial. If abnormalities are present in the chest x-ray and the symptoms persists after antibiotic treatment, the patient is diagnosed as having pulmonary TB and anti-TB treatment starts. Extrapulmonary TB is diagnosed with a combination of histology, cytology, x-ray investigations, and clinical decisions [10].

The presumptive TB cases diagnosed with TB are enrolled for treatment, and children under the age of five in whom active TB has been ruled out are started on IPT for six months. IPT administration is demonstrated to the index TB patients, who administer IPT to children at home, and verified by CHWs when they provide directly observed treatment (DOT) to the index TB patient at home.

Data collection and analysis

We collected the data from the NTP’s annual and quarterly reports for 2011–2018. The national database since 2011 reports the number of all forms of TB diagnosed, number of bacteriologically confirmed TB cases, number of contacts screened, screening results (i.e., presumptive TB cases), number of children under five registered and put on IPT, and IPT completion rate. The database does not disaggregate the number of contacts screened by age for all years, so this information is not included in the analysis. The sex difference in performance was analyzed to see if there is a gender difference in services as well as disease burden, in order to inform future recommendations. The NTP, provincial health offices, and NGOs supporting the TB program carried out quarterly data quality assurance, and the quality of data has improved over time. Individual data were entered into registers, and health facilities reported indicator-level aggregated data to provinces, which in turn aggregate the data and report it to the NTP manually. In Afghanistan there are two CHWs, one male and one female, for a population of 1,000–1,500, and most DOT is administered by CHWs. We aggregated the data by year and calculated the number needed to screen (NNS) to obtain a presumptive TB case and number needed to test (NNT) to diagnose a single case of TB. We calculated the 95% confidence intervals and p values using OpenEPI Software (Dean AG, Sullivan KM, Soe MM, OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 3.01, available from www.OpenEpi.com, updated 6 April 2013, accessed 23 Oct. 2019) and MedCalc software (Ostend, Belgium, Version 19, available from MedCalc.net, updated Aug. 2019).

Definition of terms

We defined “bacteriologically confirmed index TB case” as a patient diagnosed with AFB sputum-smear microscopy as positive or any patient diagnosed positive with GeneXpert. A household contact per WHO’s definition is “A person who shared the same enclosed living space for one or more nights or for frequent or extended periods during the day with the index case during the 3 months before commencement of the current treatment episode” [3]. A presumptive TB case is defined as having cough for two weeks or more, night sweating, and loss of weight, and, for children, failure to thrive. The NNS is defined as the number of contacts that have to be screened to detect a single case of presumptive TB, and the NNT is the number of presumptive TB cases that have to be evaluated to diagnose a single TB patient. IPT completion is defined as the completion of more than 95% of the prescribed dose of isoniazid, ascertained by TB focal persons by counting the pills in a blister pack, and DOT by CHWs when they observe the treatment of the index case.

Ethical considerations

We obtained approval from the Afghanistan NTP to use the data collected and aggregated in the MOPH Management Information System database, and no additional ethical approval was required because we used de-identified data collected from routine programmatic reports of the NTP.

Results

We analyzed a total of 298,332 TB cases between 2011 and 2018, and of those 142,797 (47.8%) were bacteriologically confirmed TB cases. Those bacteriologically confirmed TB cases were used as the index TB patients for the household contact screening. Based on data from the national census about average household size, the number of household contacts for each index TB patient was estimated to be six [12].

The yield of TB screening

From 2011 to 2018, 586,292 household contacts were screened for TB, of whom 291,995 (49.8%) were females. Out of those screened, 117,643 (20.1%, 95% CI 19.96–20.07) were identified as presumptive TB cases. The presumptive TB cases identified totaled 55,255 (18.8%) in males and 62,388 (21.3%) in females (p < 0.0001). A total of 10,896 (1.8%, 95% CI 1.82–1.89) TB cases were diagnosed among all those screened, and out of those in whom TB (all forms) was diagnosed, 6,271 (57.5%, 95% CI 56.6–58.5) were bacteriologically confirmed TB patients (Table 1 and Fig 1).

Table 1. Trends and yield of household contact investigation.

Year All TB Cases Notified Bacteriologically Confirmed TB Cases (%) Estimated No. HH Contacts to Be Screeneda No. (%) HH Contacts Screened No. (%) Presumptive TB Cases No. (%) TB (All Forms) Diagnosed among HH Contacts No. (%) Bacteriologically Confirmed TB among HH Contacts
2011 28,167 15,103 (53.6) 90,618 44,259 (49) 16,145 (36.4) 822 (1.8) 606 (73.7)
2012 29,578 14,464 (48.9) 86,784 44,766 (52) 7,939 (17.7) 610 (1.3) 350 (57.3)
2013 31,622 15,670 (49.5) 94,020 48,122 (51) 8,274 (17.2) 788 (1.6) 390 (49.4)
2014 32,712 16,182 (49.4) 97,092 53,189 (55) 9,403 (17.6) 770 (1.4) 469 (58.3)
2015 37,001 17,975 (48.5) 107,850 61,678 (57) 13,367 (21.7) 1,062 (1.7) 580 (54.6)
2016 43,046 19,948 (46.3) 119,688 85,755 (72) 15,569 (18.1) 1,544 (1.8) 894 (57.9)
2017 47,406 21,316 (44.9) 127,896 125,350 (98) 22,499 (17.9) 2,443 (1.9) 1,511 (63.4)
2018 48,800 22,139 (45.3) 132,834 123,173 (93) 24,447 (19.8) 2,857 (2.3) 1,471 (51.4)
Total 298,332 142,797 (47.8) 856,782 586,292 (81) 117,643 (20.1) 10,896 (1.8) 6,271 (57.5)

Notes: HH = household.

aThe average number of household members in Afghanistan is reported to be six.

Fig 1. Total screened, and yield of TB, Afghanistan (2011–2018).

Fig 1

Out of all those screened, 4,963 (1.7%) of the males and 5,933 (2.03%) of the females were diagnosed with TB (all forms) (p < 0.001) (Table 2). In terms of yearly performance, the number of all forms of TB diagnosed progressively increased, from 28,167 in 2011 to 48,800 in 2018, which is a 73% increase (chi-square for trend = 269.2, p < 0.01). The number of bacteriologically confirmed cases also increased, from 15,103 in 2011 to 22,139 in 2018—an increase of 46.5%. Parallel to case detection, the number of index case household members screened also increased gradually, from 49% in 2011 to 93% in 2018 (chi-square for trend = 130.9, p < 0.01). The average yield of all forms of TB diagnosed was 1.8%, and it is only in 2018 that the rate was higher, at 2.3% (Table 1).

Table 2. Yield of screening of household contacts of TB index cases by sex.

Year No. HH Contacts Screened Ratio (F/M) No. Presumptive TB Cases (%) No. TB (All Forms) Diagnosed among HH Contacts Screened (%) No. and Proportion of Bacteriologically Confirmed TB among all Forms of TB Diagnosed
M F M F M F M F
2011 21,665 22,594 1.04 7,554 (34.9) 8,591 (38.0) 340 (1.6) 482 (2.1) 222 (65.3) 384 (79.6)
2012 22,339 22,427 1.00 3,713 (16.5) 4,226 (18.8) 253 (1.1) 357 (1.6) 139 (54.9) 211 (59.1)
2013 23,536 24,586 1.04 3,872 (16.5) 4,402 (17.9) 359 (1.5) 429 (1.7) 164 (45.6) 226 (52.7)
2014 27,422 25,767 0.94 4,372 (15.9) 5,031 (19.5) 359 (1.3) 411 (1.6) 192 (53.4) 277 (67.3)
2015 30,746 30,932 1.01 6,189 (20.1) 7,178 (23.2) 485 (1.6) 577 (1.9) 235 (48.4) 345 (59.8)
2016 43,142 42,613 0.99 7,312 (16.9) 8,257 (19.4) 669 (1.5) 875 (2.0) 353 (52.7) 541 (61.8)
2017 64,072 61,278 0.96 10,619 (16.6) 11,880 (19.4) 1,161 (1.8) 1,282 (2.1) 673 (57.9) 838 (65.3)
2018 61,375 61,798 1.01 11,624 (18.9) 12,823 (20.7) 1,337 (2.2) 1,520 (2.5) 672 (50.2) 799 (52.5)
Total 294,297 291,995 0.99 55,255 (18.8) 62,388 (21.4) 4,963 (1.7) 5,933 (2.0) 2,650 (53.4) 3,621 (61.0)

The proportion of presumptive TB cases identified was 18.8% (95% CI 18.63–18.92) for males and 21.4% (95% CI 21.2–21.5) for females (p < 0.0001). The NNS to identify a single presumptive TB cases was 53.8, and the NNT to diagnose a single case of all forms of TB was 10.8. The NNS for bacteriologically confirmed TB cases was 93.5 and the NNT was 18.7 (Table 3).

Table 3. Yield of contact screening by sex.

Characteristics Male Female Total P Value
Total contacts screened 294,297 291,995 586,292
Presumptive TB cases 55,255 62,388 117,643
    Proportion 18.8 (18.63–18.92) 21.4 (95% CI 21.2–21.5) 20.0 (95% CI 19.96–20.17)
    NNS 5.3 4.6 4.9
All forms of TB 4,963 5,933 10,896
    Proportion 1.6 2.0 1.8 < 0.0001
    NNS 59.2 44.1 53.8
    NNT 11.1 10.5 10.8
Bacteriologically confirmed total 2,650 3,621 6,271
    Proportion 53.4 61.0 57.5 < 0.0001
    NNS 111.0 80.6 93.5
    NNT 20.8 17.2 18.7

Isoniazid preventive therapy

Contact screening was used as an entry point for identifying eligible children under the age of five for IPT. Out of the 586,292 household members of index TB patients screened for TB from 2011 through 2018, 117,593 children under five were eligible for IPT. Of those, 101,084 (85.9%) were initiated on IPT and 69,273 (68.5%) completed treatment. IPT coverage increased from 73% of the eligible children in 2011 to 94% in 2018. IPT completion also improved from 46% in 2011 to 74% in 2018 (p < 0.0001) (Table 4). In terms of sex, 59,873 children (50.9%) were females, and the number of male and female children who completed the full six months of IPT were 34,293 (68%) and 34,980 (69%), respectively (p < 0.005).

Table 4. IPT enrollment and completion rate for children under age five.

Year No. HH Contacts under 5 Years Eligible for IPT No. (%) HH Contacts under 5 Years Who Started IPT No. (%) HH Contacts under 5 Years Who Completed IPT
2011 8,534 6,199 (73%) 2,823 (46%)
2012 8,934 7,461 (84%) 4,808 (64%)
2013 10,620 7,690 (72%) 4,924 (64%)
2014 11,919 8,792 (74%) 6,046 (69%)
2015 11,799 10,164 (86%) 7,737 (76%)
2016 17,215 15,417 (90%) 10,387 (67%)
2017 24,656 22929 (93%) 16,049 (70%)
2018 23,916 22,432 (94%) 16,499 (74%)
Total 117,593 101,084 (85.9%) 69,273 (68.5%)

Discussion

The Afghanistan NTP increased the screening of household contacts of bacteriologically confirmed index TB patients from 49% in 2011 to 93% in 2018 (p < 0.0001). The overall number of presumptive TB cases identified was 20.1%, which is higher than the numbers of presumptive TB cases reported in Ethiopia (6.1% and 11%) [7,13], and the 3% reported in Pakistan [8], 7.5% in Accra, Ghana [9], and 3% in another Afghanistan study [7]. The yield of all forms of TB was 1.8%, which is close to 10 times higher than the estimated national incidence of TB, at 189 per 100,000, and is closer to the 1.6% reported in another study in Afghanistan [9] and the 1.7% reported in Viet Nam [5]. Furthermore, the yield of 1.8% found in this study was higher than the 0.65% in Ghana [14], 0.17% in Viet Nam [5], and 0.9% in Peru [6], but lower than the 3.6% that WHO reported [3], lower than the 3.9% reported in South Africa [15] and lower than the 2.5% reported in Ethiopia [7]. In a 21-year retrospective study in Birmingham, UK, the TB yield among smear-positive contacts screened was 7.0 [16]. The high number of presumptive TB cases identified in the routine program of Afghanistan is relatively low when considered as a proportion of all forms of TB diagnosed. It might be that health workers included people with signs and symptoms of TB but less than two weeks of history in screening; another reason for the relatively low yield could be the use of microscopy, a low-sensitivity diagnostic tool, in the majority of cases.

The other factor that should be studied is the lack of clear international guidelines about the definition of a contact. Contact screening is currently limited to the household members living under one roof, but in a traditional society like Afghanistan’s extended family members have very close daily interactions. In a study in Pakistan, screening of household contacts and neighbors within 50 m of the radius of the index TB cases yielded rates of 22.3% and 19.1% of all forms of TB, respectively [8]. Given similarities between the community structure in Pakistan and Afghanistan, we recommend including neighbors in contact screening.

We found a significant difference between females and males (p < 0.0001) in the number of all forms of TB diagnosed, which is consistent with another Afghanistan study in which the diagnosed female-male ratio was 2.1 [9], while studies in Tanzania and England (London) did not show any difference between males and females [1718].

The NNS to obtain a presumptive case of TB (all forms) was 53.8 and the NNT was 10.7. The NNS is lower than the NNS of 424 and 378 reported in the Afghanistan study [9]. In Ethiopia, the NNS and NNT were 40 and 2.4, respectively, and in Ghana, the NNS was 154 and the NNT was 8, respectively [7,14]. The NNT depends mainly on the incidence of the disease in a country, the quality of screening, and the screening tool used, so the differences among countries can be explained by these factors, but we do not know why the NNT in the other Afghanistan study was so high [9]. A different geography with a different disease burden or the capacity of the professionals involved in TB screening and diagnosis could be factors. The introduction of GeneXpert in recent years might also be a factor in the difference in results between our study and the other Afghanistan study.

The rate of bacteriologically confirmed cases in this analysis was 57.5%, which is close to the 61% reported by WHO [1]. The yield could have been higher if x-rays had been used as a screening tool and GeneXpert used as a diagnostic tool for all. As an example, in a study in Zambia, out of all contacts screened with chest x-ray, 53.6% had abnormal chest x-rays, and out of those, TB (all forms) was diagnosed in 32%; 19% of them were bacteriologically confirmed, but 8% had no symptoms [19]. Chest x-ray is highly sensitive, and most of the TB cases identified in national prevalence surveys and focal studies were found by chest x-ray rather than by symptomatic screening alone [1720]. GeneXpert is also a more sensitive and specific tool for TB diagnosis [20,21]. In the future, the introduction of chest x-ray and GeneXpert for screening and diagnosis of TB, respectively, will help to increase case detection in Afghanistan.

Contact screening was used as an entry point for IPT initiation of children under age five who were contacts of bacteriologically confirmed TB patients. According to the 2018 WHO report, Afghanistan reported 100% initiation of IPT for the year 2017 [1], while we report 93% because of updates after the data were submitted to WHO. Afghanistan is one of the few countries with a high TB incidence rate to achieve this result [1]. The completion rate for six months of IPT is also very high, with an average of 68.5% from 2011 through 2018. To our knowledge, there is no nationwide report of completion of treatment for latent TB infection on this scale except from Mozambique [1], and the reports for various smaller groups ranged from 6% to 94% [22]. We attribute the high rate of completion to the counseling of parents on the importance of IPT, including health workers’ encouragement of parents to complete children’s IPT; good follow-up with patients who missed a day of treatment; and uninterrupted supply of isoniazid. The mandatory implementation of contact registration and screening of all index TB patients in Afghanistan increased case notification and served as an entry point to find IPT-eligible children. Another advantage is that the treatment of index TB patients is observed daily, so the health worker can ask them to bring all contacts for screening. CHWs visit index TB patients at home, providing another opportunity to screen all contacts and to supervise IPT.

Limitations

Because the data for this study were collected from routine reports, and health facility registers do not include the number of household members, the denominator used to calculate the target for screening was the national average household size. Using that number might have inflated or underestimated the actual number of contacts screened. Furthermore, GeneXpert has been used since 2015 as a diagnostic method in a very small number of health facilities, but this study did not capture the results by diagnostic type for bacteriologically confirmed TB cases.

Conclusions

This study found that contact screening of household members of TB index cases in Afghanistan is very high by global standards, and the yield of TB is also close to 10 times higher than the national estimated TB incidence from 2011 through 2018 [1]. We recommend following contacts for two to three years, since most contacts who develop TB disease do so within this time period. IPT initiation and completion rates are very high, and along with the extension of contact screening to neighbors, IPT targets should also be revised. Shifting from IPT to rifapentine- or rifampicin-based shorter TB preventive treatment for latent TB infection [23] will further improve treatment completion, and the country should revise its policy to extend preventive treatment to all eligible contacts of all ages.

Supporting information

S1 File

(XLS)

Acknowledgments

We thank the teams from the NTP and Challenge TB Afghanistan for their support in the development of this paper. Erik J. Schouten assisted in reviewing the draft article, and Barbara K. Timmons edited and formatted the article. We also appreciate the support of the home office team of Management Sciences for Health.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

The United States Agency for International Development (USAID) funded this study through the Challenge TB project under cooperative agreement number AID-OAA-A-14-00029. The contents of the article are the responsibility of the authors alone and do not necessarily reflect the views of USAID or the US government. The publication fee is covered by the USAID funded Sustainable Technical and Analytic Resources (STAR) project, through Public Health Institute (PHI).

References

  • 1.World Health; Organization (WHO). Global tuberculosis report 2019. Geneva: WHO; 2019. [Google Scholar]
  • 2.Islamic Republic of Afghanistan, Ministry of Public Health, General Directorate of Preventive Medicine, Control of Communicable Diseases Directorate, National TB Program. National Strategic Plan for Tuberculosis Control 2013–2017. Available from: https://extranet.who.int/countryplanningcycles/sites/default/files/planning_cycle_repository/afghanistan/tb_plan_afghanistan.pdf
  • 3.Hopewell P, Fair E, Miller C. Recommendations for investigating contacts of persons with infectious tuberculosis in low- and middle-income countries. Geneva: WHO; 2012. Available from: http://www.ncbi.nlm.nih.gov/books/NBK179062/ [PubMed] [Google Scholar]
  • 4.Thanh THT, Ngoc SD, Viet NN, Van HN, Horby P, Cobelens FGJ, et al. A household survey on screening practices of household contacts of smear positive tuberculosis patients in Vietnam. BMC Public Health. 2014. July 11;14: 713 10.1186/1471-2458-14-713 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Fox GJ, Nhung NV, Sy DN, Hoa NLP, Anh LTN, Anh NT, et al. Household-contact investigation for detection of tuberculosis in Vietnam. N Engl J Med. 2018. January 18;378: 221–229. 10.1056/NEJMoa1700209 [DOI] [PubMed] [Google Scholar]
  • 6.Becerra MC, Pachao-Torreblanca IF, Bayona J, Celi R, Shin SS, Kim JY, et al. Expanding tuberculosis case detection by screening household contacts. Public Health Rep. 2005. June;120: 271–277. 10.1177/003335490512000309 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Jerene D, Melese M, Kassie Y, Alem G, Daba SH, Hiruye N, et al. The yield of a tuberculosis household contact investigation in two regions of Ethiopia. Int J Tuberc Lung Dis. 2015. August;19: 898–903. 10.5588/ijtld.14.0978 [DOI] [PubMed] [Google Scholar]
  • 8.Fatima R, Qadeer E, Yaqoob A, Haq MU, Majumdar SS, Shewade HD, et al. Extending “contact tracing” into the community within a 50-metre radius of an index tuberculosis patient using Xpert MTB/RIF in urban Pakistan: did it increase case detection? PLoS One. 2016. November 29;11: e0165813 10.1371/journal.pone.0165813 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Sanaie A, Mergenthaler C, Nasrat A, Seddiq MK, Mahmoodi SD, Stevens RH, et al. An evaluation of passive and active approaches to improve tuberculosis notifications in Afghanistan. PLoS One. 2016. October 4;11: e0163813 10.1371/journal.pone.0163813 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Hasam R, Barghout S. [Regional Green Light Committee] rGLC monitoring report: Afghanistan. 2018 Jul 23–25. Available from: http://www.emro.who.int/images/stories/afghanistan/rGLC_Afghanistan_Mission_Report_Final_14_Aug_2018.pdf?ua=1
  • 11.World Health Organization (WHO). Systematic screening for active tuberculosis: an operational guide. Geneva: WHO; 2015. Available from: http://apps.who.int/iris/bitstream/10665/181164/1/9789241549172_eng.pdf?ua=1 [Google Scholar]
  • 12.Islamic Republic of Afghanistan, Central Statistics Organisation (CSO). Afghanistan living condition survey 2016–2017. Kabul: CSO; 2018. Available from: https://washdata.org/sites/default/files/documents/reports/2018-07/Afghanistan%20ALCS%202016-17%20Analysis%20report.pdf
  • 13.Habte D, Melese M, Hiruy N, Gashu Z, Jerene D, Moges F, et al. The additional yield of GeneXpert MTB/RIF test in the diagnosis of pulmonary tuberculosis among household contacts of smear positive TB cases. Int J Infect Dis. 2016. August;49: 179–184. 10.1016/j.ijid.2016.07.002 [DOI] [PubMed] [Google Scholar]
  • 14.Ohene S-A, Bonsu F, Hanson-Nortey NN, Sackey A, Danso S, Afutu F, et al. Yield of tuberculosis among household contacts of tuberculosis patients in Accra, Ghana. Infect Dis Poverty. 2018. February 27;7: 14 10.1186/s40249-018-0396-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Little KM, Msandiwa R, Martinson N, Golub J, Chaisson R, Dowdy D. Yield of household contact tracing for tuberculosis in rural South Africa. BMC Infect Dis. 2018. July 4;18: 299 10.1186/s12879-018-3193-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Saunders MJ, Koh GCKW, Small AD, Dedicoat M. Predictors of contact tracing completion and outcomes in tuberculosis: a 21-year retrospective cohort study. Int J Tuberc Lung Dis. 2014. June;18: 640–646. 10.5588/ijtld.13.0486 [DOI] [PubMed] [Google Scholar]
  • 17.Cavany SM, Sumner T, Vynnycky E, Flach C, White RG, Thomas HL, et al. An evaluation of tuberculosis contact investigations against national standards. Thorax. 2017;72: 736–745. 10.1136/thoraxjnl-2016-209677 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Beyanga M, Kidenya BR, Gerwing-Adima L, Ochodo E, Mshana SE, Kasang C. Investigation of household contacts of pulmonary tuberculosis patients increases case detection in Mwanza City, Tanzania. BMC Infect Dis. 2018. March 6;18: 110 10.1186/s12879-018-3036-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Muyoyeta M, Kasese NC, Milimo D, Mushanga I, Ndhlovu M, Kapata N, et al. Digital CXR with computer aided diagnosis versus symptom screen to define presumptive tuberculosis among household contacts and impact on tuberculosis diagnosis. BMC Infect Dis. 2017. April 24;17: 301 10.1186/s12879-017-2388-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Enos M, Sitienei J, Ong’ang’o J, Mungai B, Kamene M, Wambugu J, et al. Kenya tuberculosis prevalence survey 2016: challenges and opportunities of ending TB in Kenya. PLoS One. 2018. December 26;13: e0209098 10.1371/journal.pone.0209098 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.World Health Organization (WHO). Xpert MTB/RIF implementation manual: technical and operational “how-to”: practical considerations. Geneva: WHO; 2014. Available from: http://www.ncbi.nlm.nih.gov/books/NBK254323/ [PubMed] [Google Scholar]
  • 22.Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015. December;46: 1563–1576. 10.1183/13993003.01245-2015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.World Health Organization (WHO). Guidelines on the management of latent tuberculosis infection. Geneva: WHO; 2015. [PubMed] [Google Scholar]

Decision Letter 0

Philip C Hill

17 Dec 2019

PONE-D-19-30098

Active household contact screening for tuberculosis and provision of isoniazid preventive therapy to children in Afghanistan

PLOS ONE

Dear Dr Sayedi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Jan 31 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Philip C Hill, MD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Additional Editor Comments (if provided):

Please address all the comments by the reviewers. Please note, the paper will need to be improved both scientifically and in grammatical aspects.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: No

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is an interesting study of secondary data on contact investigation, a high priority according to the UN high-level meeting held in NYC in 2018. Two previous studies have reported the prevalence of active TB among contacts in Afghanistan. The current manuscript adds a lot to these reports, by discussing LTBI treatment, uptake and completion, and by describing the substantial increase in case finding after the implementation of a new policy in the country. These findings are interesting. The manuscript, however, needs some improvements before it can be suitable for publication.

Abstract:

This abstract should be rewritten. The objectives should clearly state that a new policy was recommended by the NTP in 2011 for contact investigation and this observational study reports the findings since these recommendations.

The Methods section currently describes mainly active TB indicators (NNS and NNT) but the conclusions focus on IPT in children. The authors need to choose what their main message is and write a coherent abstract.

If the number of children starting and completing LTBI treatment is their main focus, they need to define what the national policies for contact investigation and treatment for LTBI were in 2011-2018 in the Methods section, so that the reader can understand why so many children under 5 were prescribed IPT.

In the conclusion, what do the authors call a “high” performance? Do they mean good? The findings should be interpreted in the same was they are reported in the Results section. Incidence rate is not shown in results, so the reader can not follow the conclusion. Please adjust.

The conclusion should also describe briefly how the authors explain the high rates of IPT prescription and completion when compared to other countries.

The sentence ending the abstract is misleading: Afghanistan is not a HBC, and the sentence refers to “other” HBC. Afghanistan is a high TB incidence RATE country, which is different from HBC. Please adjust.

The short title should be adjusted. The study is not about children only.

Main text:

Introduction:

This report is of interest for many other countries. Accordingly, the introduction should highlight why the investigation of contacts is important (anywhere), and just a short paragraph to explain why it is important in Afghanistan. The detailed description of the TB situation in Afghanistan should be reported in a “setting” subheading of the Methods section.

L. 32-33: Incidence and incidence rates are different concepts, please rephrase.

Methods

This is an observational study of a new policy recommended by the NTP. The new policy and the routine investigation of contacts should be explained but not be named “intervention” because this is misleading. All that is currently reported as the “intervention” should be reported as setting. This section should also make clear what were the previous recommendations and what is new in the current recommendation.

Are the reported definitions the ones adopted by the NTP? Are health care workers and community agents instructed to identify contacts as per this definition?

Data analysis: time trend would be a better analysis (quarterly, since these data is available by quarter) than proportions. The increase (or any change) in the population (denominator) should be taken into consideration in analyses/comments of incidence rates.

Ethics: how was data stored? What procedures were made to protect the data?

Results:

“We included” is not a good term for an analysis of secondary data.

The p-values are unnecessary, since the CI are presented (and any difference with such a huge sample would be “statistically significant”.

Discussion

The results should not be repeated in the discussion.

Instead of simply comparing the yield of active TB among screened contacts, it would be interesting to discuss what might explain these differences.

What does this manuscript add to the two previous reports on contact investigation in the country? This should be highlighted in the discussion. How do the current findings compare to findings before the new policy? In other words, what is the impact of the new policy? Were there any other changes in the country or health system in this period that could explain the increase in the proportion of TB cases diagnosed?

Comments on cost-effectiveness of the NNS and NNT would be interesting, even if speculative since this kind of analysis was not the scope of the study.

Above all, the conclusions cannot be withdrawn from the findings of the study.

Minor comments:

1. The text needs some language review.

2. References need to be updated.

Reviewer #2: Summary of Paper:

The manuscript summarizes 8 years of national TB program data in Afghanistan. During this time period 142, 797 active TB cases were reported and 586,292 household contacts of index cases were screened for TB. The number of co-prevalent cases among HHC was found to be high. TPT initiation and completion rates for children under five were high. In many cases data is reported separately for men and women. The number needed to screen (NNS) and number needed to treat (NNT) are also reported.

General comments:

Overall this was an informative and well written paper. Data is presented for many useful TB indicators. The performance of the program is remarkable. Some additional explanation as to how the program has been able to perform so well would be useful so that others can learn from the experience in Afghanistan.

Major comments:

1) On page 4 the authors state that they use “routine contact screen performance” data from the Afghanistan NTP from 2011-2018. It would be useful to know more about how this data is collected and how good the data is felt to be? (has the same registry been in place since 2011 to collect this data? Are they electronic registries? Do they combine data from multiple registries? How reliable are the data collected in screening registries? How complete are they?)

2) Related to the point above, within these registries how is treatment completion measured?

3) How large is the private sector in Afghanistan? If the private sector is involved in TB care, how is this captured in the data reported? Is the private sector involved in routine program reporting? The role of the private sector and the generalizability of the findings reported in the manuscript data should be included in the discussion

4) The authors show that there have been major improvement in the TB outcomes reported during this period. It would be interesting to know what mechanisms may have contributed to the major improvements seen in the country in the last few year. For example has program funding remained stable over these years? How/why has it changed? Have strengthening projects been in place? Readers will be interested to know what investments are required in order to bring a program to this level (both in terms of both $ and program strengthening through Challenge TB etc…)

5) Throughout the manuscript, the authors stratify most findings by sex, and use statistical testing to look at sex differences. It would be helpful to provide a justification in background to support these analyses. Was there an initial hypothesis that there would be gender differences which led to these analysis? I’m not sure what the statistical testing adds without a clear discussion of the rationale and implications. In the discussion there is currently just a comparison to what others have found.

6) In the paper the authors use census data to estimate 6 household members. Do the authors know how many HHC were usually identified when contact investigators were performed? Is there any data available to validate the census assumption?

7) In the discussion the authors state that they attribute the high rate of completion to various things (counseling of parents on the importance of IPT etc..). It would be nice to have more detail about what is involved programmatically in achieving this level of passive case detection, screening, testing and treatment initiation, so that others can learn from the successes of this program. For example, what is involved in good follow up? What lengths do HCW go to in order to help people initiate and complete IPT. If the authors can elaborate on any of these points it would strengthen the paper.

8) The authors final statement that IPT “should probably be extended to all eligible contacts of all ages” seems like a bit of an afterthought. For a program that is seemingly performing so well, one could argue this would be an obvious next step. Can the authors comment on if there are plans for this, or if there are obstacles? It seems that this notion deserves more attention, especially in light on the UNHLM targets to expand TPT to 20 million HHC of all ages by 2022.

.

Minor points:

9) line 110- it should be made clear that by “contact” they are referring to household contacts (based on the definition provided). Throughout would suggest referring to household contact for clarity.

10) line 114 there is a typo?- should be NNS (not NNT)

11) Line 235- typo? It states “interrupted” supply of INH- presumably it should say “uninterrupted”.

12) Page 6 the first line on page 7 (line 132) is redundant as it has already been stated in the first line of the results

13) Page 13, line 251- we recommend following contacts for 2-3 years- to monitor for TB? Pls clarify for what reasons

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2020 Oct 9;15(10):e0240031. doi: 10.1371/journal.pone.0240031.r002

Author response to Decision Letter 0


4 Aug 2020

I have attached a letter with response to comments for reviewers as revised submission document

Attachment

Submitted filename: Contact Screening Afghanistan response to reviewers.docx

Decision Letter 1

Philip C Hill

25 Aug 2020

PONE-D-19-30098R1

Active household contact screening for tuberculosis and provision of isoniazid preventive therapy to under-five children in Afghanistan

PLOS ONE

Dear Dr. Sayedi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 09 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Philip C Hill, MD

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

I am afraid the quality of the English, especially in the newly revised sections is not good enough for publication

I am happy to give you an opportunity to fix this issue.

[Note: HTML markup is below. Please do not edit.]

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2020 Oct 9;15(10):e0240031. doi: 10.1371/journal.pone.0240031.r004

Author response to Decision Letter 1


15 Sep 2020

all the data are in the article.

I have attached two documents for reviewers comments

The English editing done

An excel file with data attached

Attachment

Submitted filename: Response to Reviewers 2.docx

Decision Letter 2

Philip C Hill

18 Sep 2020

Active household contact screening for tuberculosis and provision of isoniazid preventive therapy to under-five children in Afghanistan

PONE-D-19-30098R2

Dear Dr. Sayedi,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Philip C Hill, MD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Philip C Hill

30 Sep 2020

PONE-D-19-30098R2

Active household contact screening for tuberculosis and provision of isoniazid preventive therapy to under-five children in Afghanistan  

Dear Dr. Sayedi:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Philip C Hill

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File

    (XLS)

    Attachment

    Submitted filename: Contact Screening Afghanistan response to reviewers.docx

    Attachment

    Submitted filename: Response to Reviewers 2.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES